Chapter 27 — Gastrointestinal Pharmacology — Module 4 — Inflammatory Bowel Disease Pharmacology, Part 2: Biologics and Small Molecules (Tier 2: Conceptual Understanding)
1. A patient maintained on infliximab loses response over time. Considering infliximab's molecular structure together with the principles of therapeutic drug monitoring (TDM), which integrated reasoning best predicts the mechanism most likely responsible and the testing that would confirm it?
A) Its fully human structure makes immunogenic loss impossible, so a low trough must reflect pharmacodynamic failure detectable only by mucosal biopsy
B) Its chimeric structure, containing a murine component, makes it relatively immunogenic, so anti-drug antibody formation is a leading cause of loss of response, and measuring trough drug concentration together with anti-drug antibody level would confirm immunogenic failure
C) Its lack of a fragment crystallizable (Fc) region prevents anti-drug antibody formation, so loss of response can only be pharmacokinetic and is confirmed by genotyping
D) Its small-molecule structure means hepatic cytochrome induction lowers the trough, confirmed by measuring cytochrome P450 activity
E) Its gut-selective integrin binding becomes saturated over time, confirmed by fecal calprotectin alone
ANSWER: B
Rationale:
Infliximab is a chimeric antibody whose murine component makes it relatively immunogenic, so anti-drug antibody formation is a leading cause of secondary loss of response; measuring the trough drug concentration together with the anti-drug antibody level distinguishes immunogenic failure (low trough, high antibodies) from other mechanisms.
Option A: Option A misstates infliximab as fully human; it is chimeric, and immunogenic loss is in fact common.
Option C: Option C incorrectly assigns the missing Fc region to infliximab, a property that belongs to certolizumab, and genotyping does not confirm loss of response.
Option D: Option D incorrectly treats infliximab as a small molecule subject to cytochrome metabolism, whereas it is an antibody cleared by reticuloendothelial catabolism.
Option E: Option E incorrectly attributes a gut-selective integrin mechanism to infliximab, which neutralizes TNF rather than blocking integrin.
2. Anti-TNF agents require latent tuberculosis screening before initiation, whereas vedolizumab does not. Integrating the immunologic role of TNF-alpha with vedolizumab's mechanism, which explanation correctly accounts for this difference?
A) Anti-TNF agents require screening only because of historical regulatory precedent, and vedolizumab is exempt for the same arbitrary reason
B) Both drugs equally suppress systemic immunity, but vedolizumab's screening requirement was simply never studied
C) Vedolizumab neutralizes TNF more selectively, so granulomas remain intact while anti-TNF agents do not affect granulomas at all
D) TNF-alpha maintains granuloma integrity, so anti-TNF neutralization can release latent mycobacteria and mandates screening, whereas vedolizumab's alpha-4-beta-7 blockade is compartmentalized to gut-homing lymphocytes and preserves the systemic immunity that contains latent tuberculosis
E) Vedolizumab accelerates clearance of mycobacteria, eliminating any need for screening
ANSWER: D
Rationale:
TNF-alpha is essential for maintaining the granulomas that contain latent Mycobacterium tuberculosis, so neutralizing TNF can release viable organisms and mandates pre-treatment screening; vedolizumab instead blocks the alpha-4-beta-7 integrin on gut-homing lymphocytes, an effect compartmentalized to the gut that preserves the systemic immune surveillance containing latent tuberculosis.
Option A: Option A incorrectly reduces the screening requirement to arbitrary precedent rather than granuloma biology.
Option B: Option B incorrectly claims both drugs suppress systemic immunity equally, ignoring vedolizumab's gut selectivity.
Option C: Option C incorrectly states that vedolizumab neutralizes TNF, which it does not, and wrongly claims anti-TNF agents leave granulomas unaffected.
Option E: Option E fabricates a mycobacterial clearance effect that vedolizumab does not have.
3. A patient is about to begin a Janus kinase (JAK) inhibitor for ulcerative colitis. Integrating the characteristic adverse-effect profile of JAK inhibitors with the rules governing vaccination during immunosuppression, which approach is correct?
A) Because JAK inhibitors carry an elevated risk of herpes zoster reactivation, the recombinant (non-live) zoster vaccine should be given before or as early as possible after starting therapy, while live vaccines are contraindicated during therapy
B) Because JAK inhibitors do not increase zoster risk, no vaccination is warranted
C) The live attenuated zoster vaccine should be administered during JAK inhibitor therapy to maximize immunity
D) Zoster vaccination is unnecessary because JAK inhibitors only increase the risk of tuberculosis reactivation
E) All vaccines, live and non-live, are safe and equally encouraged during JAK inhibitor therapy
ANSWER: A
Rationale:
JAK inhibitors increase the risk of herpes zoster reactivation more than biologics or conventional immunomodulators, so the recombinant (non-live) zoster vaccine should be given before or as early as possible after starting therapy, while live vaccines remain contraindicated during immunosuppression.
Option B: Option B incorrectly denies the elevated zoster risk that defines this class.
Option C: Option C incorrectly recommends a live vaccine during immunosuppression, which is contraindicated.
Option D: Option D incorrectly substitutes tuberculosis reactivation, which is an anti-TNF concern, for the characteristic JAK inhibitor zoster signal.
Option E: Option E incorrectly treats live and non-live vaccines as equally safe during immunosuppression, ignoring the live-vaccine contraindication.
4. A patient with acutely active, severe Crohn's disease needs an advanced therapy that will work quickly. Integrating the onset characteristics of the available biologics with the clinical urgency, which choice and rationale are most appropriate?
A) Vedolizumab, because its gut-selective mechanism produces the fastest possible response in severe disease
B) Vedolizumab, because onset speed is irrelevant when the disease is severe
C) An anti-TNF agent, because anti-TNF biologics act more rapidly than vedolizumab, whose onset is slower and may require weeks 10 to 14 in Crohn's disease, making it ill-suited to acute severe disease
D) Risankizumab, because selective interleukin-23 (IL-23) p19 blockade guarantees an immediate response
E) Any biologic, because all advanced therapies have identical onset times
ANSWER: C
Rationale:
Anti-TNF agents act more rapidly than vedolizumab, whose onset is slower and may require weeks 10 to 14 in Crohn's disease, so an anti-TNF agent is better suited when rapid control of acute severe disease is needed.
Option A: Option A incorrectly claims vedolizumab is fastest, when its slower onset is precisely what limits its use here.
Option B: Option B incorrectly dismisses onset speed, which is central to managing acute severe disease.
Option D: Option D incorrectly asserts an immediate response from risankizumab, which is not characterized by rapid onset in acute severe disease.
Option E: Option E incorrectly claims identical onset times across agents, ignoring the well-described differences.
5. Risankizumab selectively blocks the interleukin-23 (IL-23) p19 subunit, whereas ustekinumab blocks the p40 subunit shared by interleukin-12 (IL-12) and IL-23. Integrating these differing targets with the physiologic role of IL-12, what is the conceptual consequence of sparing IL-12?
A) Sparing IL-12 eliminates all efficacy in Crohn's disease because IL-12 is the dominant driver of inflammation
B) Sparing IL-12 converts the antibody into an oral small molecule
C) Sparing IL-12 increases the cardiovascular risk to match that of Janus kinase (JAK) inhibitors
D) Sparing IL-12 abolishes the need for any pre-treatment infection screening that ustekinumab requires
E) Sparing IL-12 preserves IL-12-dependent protective immunity, including antiviral and antimycobacterial responses, because the IL-23-driven Th17 pathway, not the IL-12-driven Th1 pathway, is the dominant pathological mechanism in inflammatory bowel disease
ANSWER: E
Rationale:
Because the IL-23-driven Th17 pathway rather than the IL-12-driven Th1 pathway is the dominant pathological mechanism in inflammatory bowel disease, selectively blocking IL-23 p19 is sufficient for efficacy while sparing IL-12 preserves IL-12-dependent protective immunity, including antiviral and antimycobacterial defenses.
Option A: Option A incorrectly designates IL-12 as the dominant driver, when the IL-23/Th17 axis predominates.
Option B: Option B incorrectly suggests that target selectivity changes the molecule into an oral small molecule, which it does not.
Option C: Option C incorrectly links IL-12 sparing to JAK inhibitor cardiovascular risk, which is an unrelated class concern.
Option D: Option D incorrectly claims that IL-12 sparing removes screening requirements, conflating cytokine selectivity with infection-screening protocols.
6. A patient on anti-TNF maintenance loses response. Therapeutic drug monitoring (TDM) shows an adequate trough drug concentration with no significant anti-drug antibodies. Integrating the three TDM-defined mechanisms of loss of response, which interpretation and action follow?
A) Pharmacokinetic failure; shorten the dosing interval to raise the trough
B) Pharmacodynamic failure, indicating a shift away from a TNF-driven mechanism; switch to a biologic of a different class rather than escalating, because additional drug cannot overcome a mechanism the target no longer drives
C) Immunogenic failure; switch to a different anti-TNF agent to evade the antibodies
D) Primary non-response; withdraw all advanced therapy permanently
E) Subtherapeutic dosing; simply double the dose of the same agent
ANSWER: B
Rationale:
An adequate trough with loss of response and no significant anti-drug antibodies defines pharmacodynamic failure, meaning the inflammation is no longer driven by the targeted pathway; the correct action is to switch to a biologic of a different class, because more of the same drug cannot overcome a mechanism the target no longer drives.
Option A: Option A incorrectly invokes pharmacokinetic failure, which requires a low trough rather than the adequate trough described.
Option C: Option C incorrectly invokes immunogenic failure, which requires high anti-drug antibodies that are absent here.
Option D: Option D incorrectly relabels secondary loss of response as primary non-response and abandons therapy inappropriately.
Option E: Option E incorrectly escalates a drug that already has an adequate level, which will not overcome a mechanism shift.
7. A patient started on an anti-TNF agent at full induction doses shows no meaningful response by week 12 (primary non-response). Integrating the biologic meaning of primary non-response with the logic of mechanism selection, what is the appropriate conclusion and next step?
A) Primary non-response implies TNF is not the dominant driver of this patient's inflammation, so the appropriate step is to switch to a biologic with a different mechanism, such as vedolizumab, ustekinumab, or a Janus kinase (JAK) inhibitor, rather than optimizing the anti-TNF dose
B) Primary non-response implies the dose was too low, so the anti-TNF dose should simply be escalated
C) Primary non-response implies immunogenicity, so an immunomodulator should be added while continuing the same agent
D) Primary non-response implies the patient will respond eventually, so the same agent should be continued unchanged
E) Primary non-response implies the diagnosis must be wrong, so all therapy should be discontinued
ANSWER: A
Rationale:
Primary non-response to an anti-TNF agent indicates that TNF is not the dominant driver of inflammation in that patient, so the appropriate step is to switch to a biologic with a different mechanism rather than optimizing the anti-TNF dose.
Option B: Option B incorrectly attributes non-response to underdosing, when escalating a drug aimed at a non-dominant pathway does not help.
Option C: Option C incorrectly attributes primary non-response to immunogenicity, which is a secondary-loss phenomenon, not the mechanism here.
Option D: Option D incorrectly assumes a merely delayed response and persists with an ineffective mechanism.
Option E: Option E incorrectly equates primary non-response with a wrong diagnosis and inappropriately abandons all therapy.
8. A pregnant patient with Crohn's disease continued infliximab past 22 weeks of gestation. Integrating the placental-transfer behavior of full IgG1 anti-TNF antibodies with neonatal immunization safety, what counseling about the infant is correct?
A) The infant requires lifelong avoidance of all vaccines because of in utero anti-TNF exposure
B) No precautions are needed because infliximab does not cross the placenta at any gestational age
C) The infant should receive extra early live vaccines to compensate for transient immunosuppression
D) Because infliximab is a full IgG1 antibody that transfers across the placenta in the third trimester, the infant's live vaccines should be delayed until about 6 months of age when the mother received anti-TNF therapy after 22 weeks
E) Certolizumab and infliximab behave identically in pregnancy, so no agent-specific counseling applies
ANSWER: D
Rationale:
Infliximab is a full IgG1 antibody that transfers across the placenta in the third trimester, so when the mother received anti-TNF therapy after 22 weeks, the infant's live vaccines should be delayed until about 6 months of age to avoid live immunization during the period of residual drug exposure.
Option A: Option A incorrectly imposes lifelong vaccine avoidance, which is not the recommendation.
Option B: Option B incorrectly claims infliximab does not cross the placenta, contradicting its third-trimester transfer.
Option C: Option C incorrectly recommends extra early live vaccines during the period of residual exposure.
Option E: Option E incorrectly equates certolizumab with infliximab, when certolizumab's lack of an Fc region makes its placental transfer minimal and its counseling different.
9. A 60-year-old patient with ulcerative colitis, hypertension, and prior coronary disease has had an inadequate response to a TNF inhibitor and asks about an oral option. Integrating the Janus kinase (JAK) inhibitor black box warning with the principles of therapy sequencing, what is the most defensible position?
A) A JAK inhibitor is contraindicated for life in anyone over 50, so it cannot be offered
B) A JAK inhibitor should be started immediately as first-line therapy because oral dosing is most convenient
C) A JAK inhibitor is a reasonable candidate given prior TNF inhibitor failure, but because this patient is aged 50 or older with cardiovascular risk factors, the decision requires careful risk-benefit assessment and explicit acknowledgment that he falls into the highest-risk group identified by the black box warning
D) A JAK inhibitor should be combined with the prior anti-TNF agent to offset cardiovascular risk
E) A JAK inhibitor is uniformly safer than any biologic and requires no cardiovascular assessment
ANSWER: C
Rationale:
Prior TNF inhibitor failure makes a JAK inhibitor a legitimate candidate, but because this patient is aged 50 or older with cardiovascular risk factors he falls into the highest-risk group identified by the black box warning, so the decision requires careful risk-benefit assessment and explicit acknowledgment of that elevated risk.
Option A: Option A overstates the warning as an absolute lifelong contraindication, which it is not.
Option B: Option B incorrectly recommends first-line immediate use, contradicting the directive to reserve JAK inhibitors for after TNF inhibitor failure.
Option D: Option D incorrectly recommends combining a JAK inhibitor with an anti-TNF agent, which compounds immunosuppression without offsetting cardiovascular risk.
Option E: Option E incorrectly claims uniform safety and waives cardiovascular assessment, which the warning specifically requires.
10. A 24-year-old man with Crohn's disease has been in deep remission for 2 years on combination infliximab plus a thiopurine. Integrating the immunogenicity benefit of combination therapy with its malignancy risk profile, what is the most appropriate consideration?
A) Continue indefinite combination therapy without reassessment, because the immunogenicity benefit always outweighs any risk
B) Stop the infliximab and continue the thiopurine alone, because monotherapy thiopurine is the safer maintenance choice
C) Add a second biologic to the regimen to deepen remission further
D) Switch to a Janus kinase (JAK) inhibitor plus thiopurine to maintain combination benefit
E) Consider withdrawing the thiopurine while continuing the biologic, because this young male in deep remission carries an elevated hepatosplenic T-cell lymphoma risk from prolonged combination anti-TNF plus thiopurine therapy, and the immunogenicity benefit must be weighed against that risk
ANSWER: E
Rationale:
A young male in deep remission on prolonged combination anti-TNF plus thiopurine therapy carries an elevated risk of hepatosplenic T-cell lymphoma, so after a sustained remission many clinicians and guidelines support withdrawing the thiopurine while continuing the biologic, weighing the immunogenicity benefit against the lymphoma risk.
Option A: Option A incorrectly asserts that the benefit always outweighs the risk and forgoes reassessment, ignoring the lymphoma concern.
Option B: Option B incorrectly keeps thiopurine monotherapy after stopping the biologic, which sacrifices disease control and does not address the combination-specific risk in the way withdrawing the immunomodulator does.
Option C: Option C incorrectly adds a second biologic, escalating immunosuppression without indication.
Option D: Option D incorrectly substitutes a JAK inhibitor plus thiopurine, perpetuating combination immunosuppression rather than reducing the malignancy risk.
11. A colleague argues that because upadacitinib is a selective Janus kinase 1 (JAK1) inhibitor, it should be free of the safety concerns that apply to pan-JAK agents. Integrating the rationale for JAK1 selectivity with the basis of the class-wide black box warning, which response is correct?
A) The colleague is fully correct; JAK1 selectivity removes both the cytopenia risk and the cardiovascular and thromboembolic risk
B) JAK1 selectivity is intended to reduce Janus kinase 2 (JAK2)-mediated effects such as anemia and neutropenia, but the class-wide black box warning for major adverse cardiovascular events, venous thromboembolism, and malignancy still applies to upadacitinib
C) JAK1 selectivity eliminates the cardiovascular risk but worsens the cytopenia risk relative to pan-JAK agents
D) JAK1 selectivity converts the drug into a biologic, exempting it from small-molecule warnings
E) JAK1 selectivity has no pharmacologic rationale and does not affect any adverse-effect profile
ANSWER: B
Rationale:
JAK1 selectivity is intended to reduce JAK2-mediated effects such as anemia and neutropenia, but it does not exempt the drug from the class-wide black box warning, so the warning for major adverse cardiovascular events, venous thromboembolism, and malignancy still applies to upadacitinib.
Option A: Option A incorrectly claims selectivity removes the cardiovascular and thromboembolic risk, which remains class-wide.
Option C: Option C incorrectly states that selectivity worsens cytopenias, when the design intent is to reduce them.
Option D: Option D incorrectly claims selectivity turns the small molecule into a biologic, which is false.
Option E: Option E incorrectly denies any pharmacologic rationale for JAK1 selectivity, contradicting its purpose of sparing JAK2-mediated effects.
12. A program adopts proactive therapeutic drug monitoring (TDM) rather than purely reactive measurement during the first year of anti-TNF therapy. Integrating the concept of proactive TDM with the mechanism by which immunogenicity develops, what is the principal rationale and a recommended timing point?
A) Proactive TDM is used only to lower drug costs and is best performed after a clinical flare
B) Proactive TDM replaces all clinical assessment, so symptoms no longer need to be monitored
C) Proactive TDM is identical to reactive TDM and offers no advantage in preventing immunogenicity
D) Proactive TDM measures trough concentrations on a schedule regardless of symptoms so that subtherapeutic levels are detected early enough to prevent anti-drug antibody development, with measurement recommended at the end of induction around weeks 14 to 16 and after dose changes
E) Proactive TDM is performed only once at the very end of the first year, after immunogenicity has already developed
ANSWER: D
Rationale:
Proactive TDM measures trough concentrations on a schedule regardless of symptoms so that subtherapeutic levels can be corrected early enough to prevent anti-drug antibody development, with measurement recommended at the end of induction around weeks 14 to 16 and after dose changes.
Option A: Option A incorrectly frames proactive TDM as a cost measure tied to flares, which describes reactive testing.
Option B: Option B incorrectly claims proactive TDM replaces clinical assessment, when drug levels are interpreted alongside symptoms and biomarkers.
Option C: Option C incorrectly equates proactive and reactive TDM, ignoring the early-detection advantage of proactive measurement.
Option E: Option E incorrectly delays measurement until immunogenicity has already developed, which defeats the preventive purpose.
13. A patient with Crohn's disease also has prominent extraintestinal manifestations, including inflammatory arthritis. Integrating the positioning principles for advanced therapies with the gut-selective versus systemic distinction, which choice is best supported and why?
A) An anti-TNF agent or ustekinumab is preferred, because systemically active agents address prominent extraintestinal manifestations, whereas gut-selective vedolizumab acts mainly within the intestine and is less suited when significant extraintestinal disease is present
B) Vedolizumab is preferred precisely because its gut-selective action treats extraintestinal arthritis most effectively
C) A Janus kinase (JAK) inhibitor is mandatory first-line in all patients with any extraintestinal manifestation regardless of prior therapy
D) Extraintestinal manifestations are irrelevant to biologic selection, so the cheapest agent should be chosen
E) Only aminosalicylates should be used because biologics do not affect extraintestinal disease
ANSWER: A
Rationale:
Systemically active agents such as anti-TNF biologics or ustekinumab are preferred when prominent extraintestinal manifestations are present, because gut-selective vedolizumab acts mainly within the intestine and is less suited to controlling significant extraintestinal disease.
Option B: Option B incorrectly claims vedolizumab best treats extraintestinal arthritis, contradicting its gut-compartmentalized action.
Option C: Option C incorrectly mandates a JAK inhibitor first-line for any extraintestinal manifestation, ignoring the directive to reserve JAK inhibitors after TNF inhibitor failure.
Option D: Option D incorrectly dismisses extraintestinal manifestations as irrelevant to agent selection, when they are an important positioning factor.
Option E: Option E incorrectly restricts therapy to aminosalicylates, which are inadequate for moderate to severe disease with extraintestinal involvement.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.